Britain and America have secured a key bilateral deal that will guarantee zero tariffs on British medicine exports entering the US market.
The Terms of the Accord
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the National Health Service (NHS). This commitment secures that tariffs on these key exports will remain at zero for a period of three years.
This development comes after earlier statements to dramatically increase tariffs on branded drug products, with potential rates mentioned up to double the cost.
"This agreement with the Britain strengthens the international landscape for innovative medicines and establishes much-needed fairness to American-British pharmaceutical trade," an announcement noted.
Commercial Importance
Drugs constitute one of the Britain's largest goods shipped to the US, which is easily the largest destination for major companies like GSK and AstraZeneca.
Export figures show that in the 12 months prior to September, the UK exported pharmaceutical products worth billions to the US. This figure made up a significant portion of total UK exports in that span.
"This deal secures work, boosts funding and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact includes several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must return to the NHS to prevent overspending will be restricted at 15%. In the past, refunds exceeded twenty percent.
Recent Tensions
The deal takes place against a ongoing dispute between the pharmaceutical industry and the ministers over medicine costs and approval rates.
These tensions were exacerbated by assertions that American patients were paying significantly more for the equivalent treatments than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward American operations.
One official stated that the NHS had to invest a greater share on treatments, noting that its spending on drugs had declined as a proportion of its total funding over the last ten years.
